Literature DB >> 29552107

Prognostic analysis of patients with locally advanced nasopharyngeal carcinoma following intensity modulated radiation therapy.

Yajie Zhao1, Lin Shen1, Xinqiong Huang1, Yuxiang He1, Jun Fu1, Yujie Qian1, Shan Li1, Na Zhao2, Liangfang Shen1.   

Abstract

The present study retrospectively analyzed the prognostic factors of 135 patients with locally advanced nasopharyngeal carcinoma (NPC) who received intensity modulated radiation therapy between August 2008 and January 2012 at Xiangya Hospital of Central South University. Patients were staged from III-IVA according to the 7th American Joint Committee on Cancer staging system. Using Statistical Analysis System 9.3 software, the present study demonstrated that, among these 135 patients, the 5-year overall survival, the 5-year local relapse-free survival, and the 5-year disease metastasis-free survival were 84, 82, and 78%, respectively. Multivariate Cox regression analysis identified that targeted treatment [hazard ratio (95% confidence interval), 2.642 (1.001, 6.972); P=0.0497] served as an independent negative prognostic factor in locally advanced NPC. The results of immunostaining revealed that the staining intensity of the radiation-resistant group was increased compared with that of the radiation-sensitive group. These results demonstrate that a high expression of EGFR may be associated with radiation resistance, and targeted treatment may not be effective in patients with locally advanced nasopharyngeal carcinoma with low expression of EGFR.

Entities:  

Keywords:  immunohistochemistry; intensity modulated radiation therapy; nasopharyngeal carcinoma; prognosis factors

Year:  2018        PMID: 29552107      PMCID: PMC5840609          DOI: 10.3892/ol.2018.7850

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

1.  Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.

Authors:  Ross Soo; Thomas Putti; Qian Tao; Boon-Cher Goh; Kang-Hoe Lee; Loh Kwok-Seng; Luke Tan; Wen-Son Hsieh
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2005-02

2.  Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim
Journal:  Ann Oncol       Date:  2012-08-16       Impact factor: 32.976

3.  Locally recurrent nasopharyngeal carcinoma.

Authors:  J T Chang; L C See; C T Liao; S H Ng; C H Wang; I H Chen; N M Tsang; C K Tseng; S G Tang; J H Hong
Journal:  Radiother Oncol       Date:  2000-02       Impact factor: 6.280

Review 4.  Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).

Authors:  Roger B Cohen
Journal:  Cancer Treat Rev       Date:  2013-10-12       Impact factor: 12.111

5.  Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.

Authors:  Xin-Qiong Huang; Xiang Chen; Xiao-Xue Xie; Qin Zhou; Kai Li; Shan Li; Liang-Fang Shen; Juan Su
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

6.  Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.

Authors:  Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

7.  Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

Authors:  D M Shin; J Y Ro; W K Hong; W N Hittelman
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

Review 8.  Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27.

Authors:  Mingli Xu; Izuru Mizoguchi; Noriko Morishima; Yukino Chiba; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  Clin Dev Immunol       Date:  2010-09-14

9.  A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer.

Authors:  Daliang Qi; Yan Cui; Qingsheng Wang; Chongbiao Huang; Jie Xu; Yanzhuo Yang; Liang Xin; Ye Tian; Xin Angelique Qi
Journal:  J Cancer Res Ther       Date:  2015-08       Impact factor: 1.805

10.  Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney.

Authors:  Suzanne E Little; Dorine A Bax; Maria Rodriguez-Pinilla; Rachael Natrajan; Boo Messahel; Kathy Pritchard-Jones; Gordan M Vujanic; Jorge S Reis-Filho; Chris Jones
Journal:  Clin Cancer Res       Date:  2007-07-23       Impact factor: 12.531

View more
  3 in total

1.  Effect of Body Size Change on Off-Center Cervical Point and Face Doses in Patients Undergoing Nasopharyngeal Carcinoma Radiotherapy.

Authors:  Meifang Fang; Lu Xu; Xianxiang Wu; Zhen Cui; Zelai He; Haoxuan Zhang; Hao Jin
Journal:  Dis Markers       Date:  2022-04-25       Impact factor: 3.434

2.  A predictive model of radiation-related fibrosis based on the radiomic features of magnetic resonance imaging and computed tomography.

Authors:  Jian Wang; Rongjie Liu; Yu Zhao; Chonnipa Nantavithya; Hesham Elhalawani; Hongtu Zhu; Abdallah Sherif Radwan Mohamed; Clifton David Fuller; Danita Kannarunimit; Pei Yang; Hong Zhu
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

3.  Influence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma.

Authors:  Zhanzhan Li; Yajie Zhao
Journal:  Cancer Manag Res       Date:  2021-06-17       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.